147 related articles for article (PubMed ID: 38263831)
1. Dosiomics for intensity-modulated radiotherapy in patients with prostate cancer: survival analysis stratified by baseline prostate-specific antigen and Gleason grade group in a 2-institutional retrospective study.
Murakami Y; Kawahara D; Soyano T; Kozuka T; Takahashi Y; Miyake K; Kashihara K; Kashihara T; Kamima T; Oguchi M; Murakami Y; Yoshioka Y; Nagata Y
Br J Radiol; 2024 Jan; 97(1153):142-149. PubMed ID: 38263831
[TBL] [Abstract][Full Text] [Related]
2. Dose-Based Radiomic Analysis (Dosiomics) for Intensity Modulated Radiation Therapy in Patients With Prostate Cancer: Correlation Between Planned Dose Distribution and Biochemical Failure.
Murakami Y; Soyano T; Kozuka T; Ushijima M; Koizumi Y; Miyauchi H; Kaneko M; Nakano M; Kamima T; Hashimoto T; Yoshioka Y; Oguchi M
Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):247-259. PubMed ID: 34706278
[TBL] [Abstract][Full Text] [Related]
3. Stability of dosiomic features against variations in dose calculation: An analysis based on a cohort of prostate external beam radiotherapy patients.
Sun L; Smith W; Kirkby C
J Appl Clin Med Phys; 2023 May; 24(5):e13904. PubMed ID: 36629276
[TBL] [Abstract][Full Text] [Related]
4. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
5. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
6. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
Hung AY; Levy L; Kuban DA
Cancer J; 2002; 8(6):440-4. PubMed ID: 12500852
[TBL] [Abstract][Full Text] [Related]
7. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.
Hanks GE; Hanlon AL; Schultheiss TE; Pinover WH; Movsas B; Epstein BE; Hunt MA
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):501-10. PubMed ID: 9635695
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
Van den Broeck T; van den Bergh RCN; Arfi N; Gross T; Moris L; Briers E; Cumberbatch M; De Santis M; Tilki D; Fanti S; Fossati N; Gillessen S; Grummet JP; Henry AM; Lardas M; Liew M; Rouvière O; Pecanka J; Mason MD; Schoots IG; van Der Kwast TH; van Der Poel HG; Wiegel T; Willemse PM; Yuan Y; Lam TB; Cornford P; Mottet N
Eur Urol; 2019 Jun; 75(6):967-987. PubMed ID: 30342843
[TBL] [Abstract][Full Text] [Related]
10. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
[TBL] [Abstract][Full Text] [Related]
11. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
12. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer.
Song C; Kang T; Yoo S; Jeong IG; Ro JY; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Feb; 31(2):168-74. PubMed ID: 21719325
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis.
Hayashi N; Osaka K; Muraoka K; Hasumi H; Makiyama K; Kondo K; Nakaigawa N; Yao M; Mukai Y; Sugiura M; Takano S; Ito E; Kaizu H; Koike I; Hata M; Taguri M; Miyoshi Y; Izumi K; Kawahara T; Uemura H
World J Urol; 2020 Oct; 38(10):2477-2484. PubMed ID: 31875247
[TBL] [Abstract][Full Text] [Related]
14. The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups.
Ricco A; Manahan G; Lanciano R; Hanlon A; Yang J; Arrigo S; Lamond J; Feng J; Mooreville M; Garber B; Brady L
Front Oncol; 2016; 6():184. PubMed ID: 27602330
[TBL] [Abstract][Full Text] [Related]
15. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
16. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
17. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
[TBL] [Abstract][Full Text] [Related]
18. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
[TBL] [Abstract][Full Text] [Related]
19. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
[TBL] [Abstract][Full Text] [Related]
20. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.
Zelefsky MJ; Hollister T; Raben A; Matthews S; Wallner KE
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1261-6. PubMed ID: 10889379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
